ReviewJournal of inflammation research2026
PANoptosis as a Potential Therapeutic Target in Drug-Induced Liver Injury: A Narrative Review.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis is a recently characterized form of programmed cell death defined by the coordinated regulation of pyroptosis, apoptosis, and necroptosis mediated by the multi-protein PANoptosome complex, a phenomenon that cannot be fully explained by any individual pathway. The initiation of PANoptosis relies on the assembly and activation of the PANoptosome, a process that has been closely linked to the onset and progression of multiple disorders, including inflammatory and neurodegenerative diseases, cancer, and pulmonary conditions. However, the contribution of PANoptosis to drug-induced liver injury (DILI) has not been thoroughly evaluated. DILI is a frequently encountered clinical adverse drug reaction, and its development is strongly associated with hepatocyte death. Therefore, this review aims to summarize the molecular mechanisms underlying PANoptosis and the assembly of the PANoptosome complex, elucidate the interactions among apoptosis, necroptosis, and pyroptosis, and assess the potential involvement of PANoptosis in DILI. Furthermore, investigating natural products that inhibit PANoptosome assembly or target key regulators such as ZBP1, AIM2, and NLRP3 to modulate PANoptosis may offer promising therapeutic opportunities for the management of DILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.